TABLE 2.
Parameter | Result for indicated genotype
|
Relationshipa | Reference(s) | |
---|---|---|---|---|
Ets1ΔVII | Ets1 knockout | |||
ETS1 expression | ||||
Full-length p51-Ets1 protein | None | Very low neomorphb | S | 7 |
ΔVII p42-Ets1 protein | High | Very low neomorphb | D | 7 |
Thymus | ||||
Cellularity | 60% increased | 65% reduction | D | 4, 7 |
CD4−CD8+ thymocytes | Expanded | Diminished | D | 7 |
Proliferation | Increased | Undocumented | ||
Apoptosis | Decreased | Increased | D | 6, 11, 12, 40 |
Spleen | ||||
Size | Decreased | Undocumented | ||
Proliferation | Increased | Decreased (T cells) | D | 40 |
Apoptosis | Increased | Increased | S | 6, 40 |
NK cells | Present | Absent | D | 4 |
CD44hi splenocytes | Diminished | Expanded | D | 7 |
Systemic | ||||
Lethality | 33% pre- or perinatal | 50% pre- or perinatal | S | 6, 7, 12 |
Rapid IFN-γ secretion | Diminished | Diminished | S | 6, 7, 12 |
Peripheral lymphopenia | Yes | Yes, but abnormal | D | 7, 12 |
S, similar phenotypes for Ets1ΔVII mice and (previously reported) Ets1-targeted mice; D, divergent phenotypes for these two strains.
The Ets1-targeted allele has been demonstrated to generate protein from in-frame splicing from exon II to exon V at ∼1 to 5% of wild-type expression levels. Also, this variant undergoes alternative splicing of exon VII to generate a neomorphic p42-Ets1 (p29).